EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Durable effectiveness and safety of hybrid ablation versus catheter ablation: 2-year results from the randomized CEASE-AF trial

Nicolas Doll, Timo Weimar, Dariusz A Kosior, Alan Bulava iD, Ales Mokracek, Gerold Mönnig, Jonathan Sahu iD, Steven Hunter, Maurits Wijffels, Bart van Putte, Norman Rüb, Petr Nemec und 3 weitere

European Journal of Cardio-Thoracic Surgery · 2025

DOI: 10.1093/ejcts/ezaf146 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Nicolas Doll und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Cardiac Surgery, Schüchtermann-Klinik, Bad Rothenfelde, Germany. Hauptthemen laut MEDLINE: Catheter Ablation, Atrial Fibrillation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AtriCure, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES The CEASE-AF trial demonstrated that epicardial-endocardial hybrid ablation (HA) had superior effectiveness compared to endocardial catheter ablation (CA) for non-paroxysmal atrial fibrillation (AF), without significantly increasing major complications during a 12-month period. Most contemporary AF ablation trials have not evaluated durability beyond 12 months. Therefore, 24-month effectiveness and safety of HA and CA are compared. METHODS CEASE-AF is a prospective, multicentre, randomized trial. Patients 18–75 years of age with symptomatic, drug refractory persistent AF and left atrial diameter >4.0 cm or long-standing persistent AF were randomized 2:1 to HA (posterior wall and pulmonary vein isolation with left atrial appendage exclusion) or CA (pulmonary vein isolation). Secondary effectiveness was freedom from AF/atrial flutter/atrial tachycardia off class I/III anti-arrhythmic drugs except for those who previously failed at doses not exceeding those previously failed through a 24-month follow-up period. Major complications and reinterventions were evaluated. RESULTS The intention-to-treat population was 102 patients with HA and 52 patients with CA. Seventy-five percent were male, 80.5% had persistent AF and 19.5% had long-standing persistent AF, with a mean age of 60.7 ± 7.9 years. Effectiveness for 24 months was 66.3% (63/95) with HA and 33.3% (17/51) with CA [absolute difference 33.0% (95% confidence interval 14.3%, 48.3%; P < 0.001)]. Major complication rates were 10.8% (11/102) with HA and 9.6% (5/52) with CA (P = 1.0), and fewer patients had reinterventions after HA than CA [18.9% (18/95) vs 52.9% (27/51), P < 0.001]. CONCLUSIONS CEASE-AF demonstrated that the 32.4% absolute benefit of HA over CA for 12 months was durable for 24 months at 33% with continued similar safety rates and fewer reinterventions after HA (funded by AtriCure, Inc.; NCT02695277). Clinicaltrials.gov registration NCT02695277

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheter AblationAtrial FibrillationHumansMaleFemaleMiddle AgedAdultAgedTreatment OutcomeProspective StudiesYoung AdultAdolescentPulmonary VeinsEndocardium

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationHybrid ablationLeft atrial appendageSurgical ablation

Autor:innen und Institutionen

  • Departement of Cardiac Surgery, Schüchtermann-Klinik, Bad Rothenfelde, Germany.
  • Eberhard Karls University, School of Medicine, Tuebingen, Germany.
  • National Medical Institute of the Ministry of Interior and Administration, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
  • Department of Cardiology, Ceske Budejovice Hospital, Czech Republic.
  • Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice, Czech Republic.

ORCID-Profile: Alan Bulava, Jonathan Sahu

Förderung

  • AtriCure, Inc

Zitieren

APA

Doll, N., Weimar, T., Kosior, D. A., Bulava, A., Mokracek, A., Mönnig, G., Sahu, J., Hunter, S., Wijffels, M., van Putte, B., Rüb, N., Nemec, P., Ostrizek, T., Fransen, E., & Suwalski, P. (2025). Durable effectiveness and safety of hybrid ablation versus catheter ablation: 2-year results from the randomized CEASE-AF trial. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf146

Vancouver

Doll N, Weimar T, Kosior DA, Bulava A, Mokracek A, Mönnig G, et al. Durable effectiveness and safety of hybrid ablation versus catheter ablation: 2-year results from the randomized CEASE-AF trial. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf146

BibTeX
@article{Doll2025,
  author = {Doll, Nicolas and Weimar, Timo and Kosior, Dariusz A and Bulava, Alan and Mokracek, Ales and Mönnig, Gerold and Sahu, Jonathan and Hunter, Steven and Wijffels, Maurits and van Putte, Bart and Rüb, Norman and Nemec, Petr and Ostrizek, Tomas and Fransen, Erik and Suwalski, Piotr},
  title = {Durable effectiveness and safety of hybrid ablation versus catheter ablation: 2-year results from the randomized CEASE-AF trial},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2025},
  doi = {10.1093/ejcts/ezaf146}
}
Kostenlos starten →